RSV vs Flu vs COVID in Adults: How to Tell Them Apart and When to See a Doctor

Research-informed explainer — last updated April 12, 2026

RSV, influenza, and COVID-19 are three different viruses that cause overlapping respiratory syndromes — but they differ meaningfully in who they hit hardest, how quickly they progress, what treatments are available, and which vaccines now exist. Knowing these differences helps you decide when to test, when to treat, and when to go to the emergency department.

This article draws on research from Kathleen Neuzil, MD, at the University of Maryland, who co-authored the mRNA COVID-19 vaccine preliminary reports and published the landmark study on influenza hospitalizations in children; Camille Kotton, MD, Clinical Director of Transplant and Immunocompromised Host Infectious Diseases at Massachusetts General Hospital, who co-authored the ACIP recommendations for the newly approved RSV vaccines; Rajesh Gandhi, MD, Professor of Medicine at Harvard Medical School and Director of HIV Clinical Services at Massachusetts General Hospital, whose clinical characterization of mild and moderate COVID-19 defined what outpatient disease looks like; and Eleftherios Mylonakis, MD PhD, Chair of Medicine at Houston Methodist, whose Google Trends surveillance paper demonstrated the predictable seasonal patterns of respiratory virus circulation.

Comparison at a Glance

RSV in Adults: An Underrecognized Threat

RSV was long considered a disease of infants and young children. That framing has shifted dramatically. CDC estimates that RSV causes 60,000-120,000 hospitalizations and 6,000-10,000 deaths annually in U.S. adults aged 65 and older — comparable in magnitude to influenza in some seasons.

In adults, RSV typically presents with 2-4 days of upper respiratory symptoms — nasal congestion, runny nose, mild sore throat — followed by a lower respiratory phase with cough and, in high-risk patients, progressive wheezing or shortness of breath. Adults with underlying COPD, heart failure, or immunosuppression are at high risk for RSV lower respiratory tract infection progressing to respiratory failure requiring hospitalization.

There is currently no approved outpatient antiviral for RSV in adults. Management is supportive — hydration, fever management, supplemental oxygen when needed. This makes prevention through vaccination the only effective intervention. In 2023, the FDA approved the first RSV vaccines for adults: GSK's Arexvy and Pfizer's Abrysvo, both for adults aged 60 and older. Dr. Kotton's ACIP guidance (cited 304 times) described a shared clinical decision-making framework — not universal recommendation — for this age group, acknowledging that benefits are highest in adults 65+ or with underlying conditions.

Influenza: The Fastest-Acting of the Three

Influenza is distinctive for its abrupt onset. Patients often recall exactly when they felt well and when they did not — typically within hours of symptom start. High fever (38.5-40°C), severe myalgia, headache, and profound fatigue are the cardinal features that distinguish flu from RSV and most COVID-19 presentations.

Dr. Neuzil's New England Journal of Medicine paper (cited 1,105 times) documented the substantial healthcare burden of influenza in children — excess hospitalizations, outpatient visits, and antibiotic courses — providing foundational epidemiologic data that shaped annual flu vaccination policy. Annual vaccination remains the most effective individual intervention against flu: vaccine effectiveness in a matched season is 40-60%, and in well-matched seasons can reach 70-80%.

When influenza is diagnosed within 48 hours of symptom onset, antiviral therapy with oral oseltamivir (Tamiflu) or inhaled zanamivir (Relenza) reduces illness duration by approximately 1 day and reduces the risk of hospitalization in high-risk groups. Treatment after 48 hours is still considered in severe or hospitalized cases.

COVID-19: Variable Presentation, Multiple Waves of Virus Evolution

Dr. Gandhi's New England Journal of Medicine paper on mild and moderate COVID-19 (cited 1,355 times) characterized the typical outpatient clinical course: median symptom onset 4-5 days after exposure, with cough, fever, and shortness of breath as the most common symptoms. Loss of smell and taste — characteristic of early pandemic variants — has become less prevalent with Omicron and subsequent variants.

Dr. Gandhi's Annals of Internal Medicine transmission review (cited 794 times) established that airborne transmission via respiratory aerosols is the dominant route, with contact and fomite transmission playing secondary roles. This understanding underpins the continued recommendation for high-quality masks (N95 or KN95) in high-risk settings.

COVID-19 continues to evolve. Updated mRNA vaccines co-developed with input from Dr. Neuzil's group (mRNA preliminary report cited 3,453 times) are reformulated annually to match circulating variants. Oral antiviral treatment with nirmatrelvir/ritonavir (Paxlovid) is highly effective (89% reduction in hospitalization) when started within 5 days of symptom onset in high-risk patients. It is recommended for anyone aged 65+, or with chronic illness, who tests positive.

When to Seek Immediate Care

All three viruses can cause life-threatening illness. Emergency evaluation is warranted for any of the following:

• Shortness of breath at rest or worsening rapidly
• Oxygen saturation below 94% (measurable with an inexpensive pulse oximeter)
• Confusion or altered mental status
• Persistent chest pain or pressure
• Inability to keep fluids down for more than 12 hours
• Lips, fingernails, or skin turning blue
• High-risk patients who develop moderate fever in the first 48 hours of illness

Prevention: Vaccines for All Three Viruses Now Exist

For the first time, adults age 60 and older can be vaccinated against all three major respiratory viruses:

• Influenza — Annual updated vaccine, recommended for everyone 6 months and older
• COVID-19 — Annual updated mRNA vaccine, strongly recommended for adults 65+
• RSV — Single dose Arexvy or Abrysvo for adults 60+, per shared clinical decision-making with your physician; also available as maternal vaccine (Abrysvo) during weeks 32-36 of pregnancy

Dr. Kotton co-authored all three MMWR ACIP guidance documents (2023) covering nirsevimab for infants, RSV vaccine for older adults, and maternal RSV vaccine during pregnancy. The convergence of all three approvals in a single season represents a historic shift in respiratory virus prevention.

Questions to ask your doctor

• Should I get the RSV vaccine this year, given my age and health conditions?
• Do I have comorbidities that make me high-priority for outpatient COVID-19 antiviral treatment?
• What is the best rapid test I can use at home to distinguish COVID-19 from flu?
• If I have COPD or heart failure, what specific warning signs should prompt a same-day call for RSV or flu?
• How does timing of my flu and COVID vaccines affect their effectiveness?
• Is there a combined flu/COVID vaccine available this season?

The bottom line

RSV, influenza, and COVID-19 cause overlapping respiratory syndromes but differ meaningfully in onset pattern, who they harm most, and what can be done. Influenza hits abruptly with severe myalgia; RSV tends to cause gradual nasal congestion followed by lower respiratory involvement in high-risk adults; COVID-19 has become more variable in presentation across variants. For the first time, vaccines against all three are available for high-risk adults — and for COVID-19 and influenza, effective outpatient antivirals exist when treatment begins early enough.